A review of 10 articles finds that nearly 9% of adverse event (AE) reports with biologics used to treat psoriasis were gastrointestinal (GI)-related and suggests that the relative rate may be higher ...

Rectal adenocarcinoma, eosinophilic esophagitis, inflammatory bowel disease, diverticular perforation, and irritable bowel syndrome are among the gastrointestinal adverse events associated with the ...

Posters presented at the American Academy of Dermatology Annual Meeting identified significant undertreatment of psoriasis and significant gaps in biologic medication treatment. This content was ...

Among patients with inflammatory bowel disease (IBD), overlapping biologic therapy was common during medication switches and was not associated with a higher risk for infection than nonoverlapping ...